Blog
RSS FeedPosted by Michael Wonder on 18 Sep 2019
Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications
16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...
Posted by Michael Wonder on 18 Sep 2019
NICE recommends Takhzyro
18 September 2019 - NICE - a health technology appraisal body in England and Wales - has recommended the use ...
Posted by Michael Wonder on 16 Sep 2019
HTA in the European Union: osteoporosis screening without proof of benefit
16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...
Posted by Michael Wonder on 16 Sep 2019
Lenvima to get benefit as first-line treatment of hepatocellular carcinoma
16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...
Posted by Michael Wonder on 16 Sep 2019
EMA publishes agenda for 16-19 CHMP meeting
13 September 2019 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 14 Sep 2019
Defining capacity building in the context of HTA: a proposal by the HTAi Scientific Development and Capacity Building Committee
11 September 2019 - A review of capacity building activities undertaken by HTAi members, members of the International Network of Agencies ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 12 Sep 2019
SMC U-turn for Vertex’s CF drugs
12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...
Posted by Michael Wonder on 11 Sep 2019
NICE publishes its 600th technology appraisal guidance
12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 10 Sep 2019
ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate
10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 09 Sep 2019
SMC - September 2019 decisions
9 September 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for cystic fibrosis
6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being ...